Newsfeeds - Spark Newswire

3 minute read

AIM ImmunoTech Announces Publication Of New Analysis Of The Mechanism Of Action Of Ampligen As A Potential Prophylactic Therapy Against Ebola Virus Disease

Today, 3:45 AM

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and

AIM

4 minute read

Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 3:45 AM

Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.

ACER

4 minute read

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 3:45 AM

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.

AIM

8 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 3:45 AM

On Thursday, 116 companies set new 52-week lows.

AHPI

3 minute read

Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket

By Lisa Levin

Today, 3:45 AM

Gainers Expion360 Inc. (NASDAQ: XPON) shares rose 152% to $2.47 in pre-market trading. Expion360 been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer available through SUV dealerships nationwide.

$APE

17 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 3:45 AM

During Friday's trading, 293 companies set new 52-week lows.

ACEL

1 minute read

AIM ImmunoTech Announces Abstract Accepted For Poster Presentation At British Society For Immunology Congress 2022 Dec. 7

By Benzinga Newsdesk

Today, 3:45 AM

Poster No: P-220 Title: Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects Presenter: Lisanne C.A. Smidt -

AIM

7 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 3:45 AM

During Wednesday's session, 107 stocks hit new 52-week lows.

AAP

6 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 3:45 AM

On Tuesday, 89 companies set new 52-week lows.

$APE

1 minute read

AIM ImmunoTech Q3 EPS $(0.13) Down From $(0.08) YoY

By Benzinga Newsdesk

Today, 3:45 AM

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.13) per share. This is a 62.5 percent decrease over losses of $(0.08) per share from the same period last year.

AIM